We’re recruiting at THE PLANNING SHOP and we have a number of great positions to fill. If you’re looking for any of the following roles, check out our career’s page to find out more:
- Associate Directors
- Research Executive
- Senior Research Director
- Field Manager
Press the ‘Check Opportunities’ button for full job details.
The 2021 Intellus Worldwide Summit starts today (April 8) and we’re looking forward to it! This year’s theme is about how to ADAPT insights, analytics and marketing for healthcare in a changing world:
How to ANTICIPATE the changes coming next
How to DISCOVER new knowledge
How to APPLY appropriate solutions
How to PARTNER to co-create and share learnings
How to TRANSITION and purposefully evolve.
It looks set to be a great virtual event where we’ll learn, increase our skills, and connect with our fellow members from the Intellus healthcare community.
We’re pleased to announce two recent team member promotions at THE PLANNING SHOP, which is a great start to a New Year!
Leia Bagge – promoted to Senior Research Executive
Leia joined TPS in 2019 as a Research Executive. Since then she has consistently displayed her dedication to the job, thorough project management skills and quantitative knowledge.
She always searches for new opportunities to develop further, voluntarily taking the lead on client initiatives.
Outside of her core role, she also makes several contributions to the wider company: she is part of the Data Science Team, the Vibes Team and she supports/coaches team members on quantitative project management.
Well done on your promotion Leia!
Nick Baboolal – promoted to Senior Research Executive
Nick joined THE PLANNING SHOP as a Research Executive in 2019. He arrived with a can do attitude, great positive energy and a fresh perspective.
Nick is proactive and creative when generating insights. He has also been instrumental in various innovation projects and TPS initiatives.
Nick truly embodies our brand essence, fearlessly pursuing the unthinkable.
Congratulations on your promotion Nick!
Chela has recently joined THE PLANNING SHOP as a Commercial Operations Specialist.
Following a Bachelor of Arts in Communications with a concentration in Advertising and Market Research from Temple University, she held roles as a Senior Field Coordinator at Health Strategies Insights, and a Research Associate in Quantitative Field at MarketVision Research.
At THE PLANNING SHOP Chela will support and maintain our MIS as well as manage project related financial information. She will also act as the liaison between the Field, Finance and Operations teams.
Chela’s hometown is Elizabeth City, NC, however she is now local to the Philadelphia, PA area. In her free time, Chela loves to travel and has a goal set to visit every continent.
Please join us in welcoming Chela!
Thank you to everyone who took part in last year’s TPS annual Season’s Greetings Calendar competition.
We had a great response, receiving 565 entries in total! Amazing!
We’re pleased to announce the winners below (the names of which were drawn from a virtual hat):
Congratulations to all the winners and everyone who got the correct answers throughout December! It was a pleasure to communicate with you in the run up to the Holidays.
Look out for 2021 calendar later this year.
The American Society of Hematology (ASH) is hosting its 62nd Annual Meeting and Exposition this weekend (5 – 8 December 2020), and Jeremy Smith, (Senior Director, Client Strategy) from THE PLANNING SHOP will be attending.
Described as “The world’s most comprehensive hematology event of the year”, the meeting provides an invaluable educational experience and opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology.
Jeremy is very much looking forward to attending and gathering knowledge about everything from immunotherapy in multiple myeloma, to improving symptom control for children with hematological malignancies, to managing toxicities of targeted therapies in CLL.
If you’re attending the event, we hope you enjoy it and find it useful. And, as Jeremy is looking forward to some online networking, so be sure to look out for him in any of the topic chat rooms.
Our annual Season’s Greetings calendar is back and it starts today! We invite you to participate, and we hope you enjoy it as much this year as in previous years.
How does it work?
In the days leading up to 24 December 2020, click on the 24 windows and answer any (or all) of the puzzles for a chance to win one of 10 splendid prizes.
Our puzzle theme this year is healthcare and humanity trends, and there are three types of puzzle: anagrams, no vowels and initials.
When you know the answers, simple email your entries to us. You can do this on the day of the puzzle or retrospectively until December 24 2020.
In the second week of January we’ll draw 10 lucky winners at random from all the entries we receive. Only one entry can be received per puzzle, however the more puzzles you submit entries for across December, the more chances you have of winning a prize (T&Cs apply).
The puzzle competitions close on Thursday 24 December 2020 at 23.59 (GMT) and are open to clients and contacts of THE PLANNING SHOP.
The winners, as well as the answers to the puzzles, will be announced on our website in the second week of January 2021.
Don’t forget to check the calendar every day if you enjoy the puzzles!
Thank you for your support during 2020! Here’s to 2021!
We’re pleased to announce the arrival of three new team members at THE PLANNING SHOP. Meet Veronica Moore, Dawn Farber and Nicky Kearney!
Senior Research Executive
Following a degree in Marketing and Biology at Fairfield University, Connecticut, Veronica joined McCann Echo, as a project manager. During her time there she worked on a variety of brands in different therapy areas. After some time at Echo, Veronica worked in project management at a small firm focused on the recruitment, retention and engagement of patients for clinical trials. She’s now excited to bring her experience to THE PLANNING SHOP and focus on another aspect of the pharmaceutical marketing process, whilst developing her research skills.
Veronica lives in Boston with her boyfriend and puppy, Minot. She enjoys yoga, running, and orange theory fitness. She also loves to spend time with her family, relaxing on a beach and travelling (in a COVID-free world).
Dawn has been a market researcher for 20 years, concentrating primarily on quantitative research. She first developed an interest in market research in college at UMASS Dartmouth, when she took a market research class to help a small local business. She became hooked on research, and straight out of college secured her first research job.
Dawn’s experience in market research includes consumer packaged goods, financial services, healthcare, and pharmaceutical research – always on the supplier side.
For fun, Dawn likes to travel with her husband, nieces and nephews. Favourite places have been Disney World, Hawaii and Aruba. Dawn also likes to read, exercise and knit (we’ll be putting our requests in for blankets, scarves and hats this Winter!). Dawn teaches group fitness classes at the local gym and likes to walk and hike.
Nicky has a deep, heartfelt passion for learning about people, and learning from people. This insatiable curiosity has served her work well.
Nicky started her career working in the advertising sales sides of radio, TV and print and then moved into a boutique firm where research, strategy and implementation were all intertwined. While she has worked with clients in the public sector (on projects such as transit for people with disabilities), B2B and B2C (ask her about ice cream in-home use tests!), her love is healthcare in all varieties. In fact, Nicky started volunteering with patients in Recreational Therapy when she was 14, and continued volunteering with her local hospice until a few years ago.
On a personal note, Nicky and her husband care for their moms (both in their late 80’s), foster Boston Terriers and help a family of 16 refugees in their area. They love to cook, attend live music (during non-pandemic times), nap, hike and read… not always in that order.
Welcome to the team Veronica, Dawn and Nicky! It’s great to have you here.
Watch our latest webinar to hear Michael Dumigan, Global Brand Consultant, at THE PLANNING SHOP talk to Dominic Tyer, Interim Managing Editor at Pharmaphorum, about the importance of emotional empathy in driving brand equity, and how the pandemic has forged pharmaceutical brands into better shape. It’s a great listen!
Let us know what you think of the issues discussed.
You can also read the full article that accompanies the webinar here.
The pandemic forges pharmaceutical brands into better shape
By Michael Dumigan, Global Brand Consultant, THE PLANNING SHOP
Day by day it becomes clearer that some brands are coming through the
pandemic in better shape than ever. These are the brands that have
clearly demonstrated emotional intelligence, that have shown emotional empathy to their target audience. They understand the current, heightened emotional state of their customers and respond to it in ways that show they give a damn.
Sometimes it is just about style and tone: like a mother’s soothing words to a
crying child that create immediate comfort and calm. Sometimes they go further, and like that same mother applying a soothing balm to a grazed knee, show by their action that they care.
The emotional wave of the moment is all about reliability, the calm in the
storm, the trusted friend. Think of the sourdough craze or the social media
frenzy around banana bread: in these times of unprecedented uncertainty in relation to life’s fundamentals – health and livelihood – we are reaching out for the warmth of a well-worn comfort blanket.
Simple kindness is one such comfort blanket. Something we want to receive
and something we want to give. Each of us is touched by the countless acts of community kindness being shown to the vulnerable. We see the dedication of healthcare workers – or of the shelf-filler in our local store – and we are moved to thank them and to make our own contribution.
Non-pharma brands leading by example
Something was broken before Covid-19 came along. The 2019 Edelman Global Trust Barometer showed levels of mistrust in business to be stratospheric, at their highest point ever. Government and the media didn’t fare any better. Of these three societal pillars, it is, perhaps surprisingly, business that has stepped up to the plate most assuredly in 2020 – led by some of the world’s strongest brands.
Brands are contributing in myriad different, relevant and engaging ways. T-Mobile went into partnership with Verizon, AT&T, and iHeartMedia to give 40,000 phone chargers to hospitals, putting frightened, isolated patients back in touch with loved ones. Verizon also donated $2.5 million to small businesses to support the Local Initiatives Support Corporation and has offered special prices for nurses and teachers. These are acts of kindness appropriate to both the brands and the situation.
Kindness starts with colleagues. Starbucks extended its mental health benefits for members of the team. In partnership with Lyra Health, Starbucks offer personalized, confidential mental health care, free in-person or video sessions, and access to a provider network of mental health therapists and coaches. Microsoft keeps on paying support staff who earn an hourly wage even when there’s nothing much for them to do.
The pandemic is global, so let’s take a quick peak at some beautiful
examples from around the globe.
- In the Philippines, Coca-Cola handed over its precious advertising space to support the Covid-19 relief and response efforts of local
- Bacardi switched production from its famous rum to
ethanol so that hand sanitiser could be manufactured in bulk. Louis
Vuitton did much the same thing in France.
- PepsiCo and partners have provided one million meals a week to rural children in need across the US and Puerto Rico.
- LinkedIn threw open many of its learning courses for free.
- Nickelodeon launched a free site to keep kids out of their parents’ hair.
- In Britain, the venerable BBC launched BBC Bitesize to help parents home-school children. They even launched virtual church services, presumably so those parents could pray for the schools to reopen!
- New York Magazine, the New York Times and The Economist
amongst many other news organisation knocked down their paywalls for COVID-19-related coverage to keep readers informed in a rapidly changing and often confusing environment.
- At Delta Airlines, the CEO ripped up his pay-check for the year to try and diminish layoffs.
- Bank of America halted foreclosure sales, evictions and repossessions.
- CVS facilitated COVID-19 testing in secure areas of parking lots at select stores. Individuals tested haven’t had to leave their car or step into the store.
Big pharma surprises itself
The pharmaceutical industry, often depicted as public enemy number one, has (with a gargantuan leap into the future), seemed to catch the public mood and respond appropriately. There is a scale difference in this transformation.
Look at the Harris pole quoted in Fierceparma on 2nd September: when asked about all pharma companies in general, regardless of whether they are working on a vaccine, 71% overall said the pharma industry is a trustworthy source. The highest-ranked sources in the poll were local doctors and nurses, trusted by 88% on average. The well-known hospitals and scientist categories tied for second at 84%. Still, pharma has come a long way over the course of the pandemic.
In 2017 Pfizer was one of the top ten US donors of charitable aid, to the tune of a staggering $210million (or 1.7% or profits) according to the Chronicle of Philanthropy, yet still, the organisation doesn’t even appear on the 2019 Axios Harris poll of top 100 reputation ranking. In 2018 the research firm Reputation Institute ranked Pfizer’s reputation at rock bottom on a list of 22 pharma companies – and none of them ranked highly against other sectors!
The data isn’t public yet but today Pfizer holds its head up high and talks
about reputation openly and assuredly: clearly confident that there has been a change and that there is more to come. How did that happen? Pfizer has shown remarkable emotional intelligence at a corporate brand level.
The change is local and global. To take one local example, in the UK Pfizer
is working with the National Schools Partnership to make its Superbugs and
Vaccines education program suitable for home learning. Over at corporate HQ, the ambition is as big as it gets, of the moon-shot order in fact, when it comes to defeating Covid-19. Pfizer has four different mRNA platform vaccines in play against one-another: a radical new approach for them. Their chief, Albert Bourla, quoted in Forbes magazine in May, made the new way of thinking and working crystal clear to his team:
“Think in different terms…Think you have an open cheque book…Think
that we will do things in parallel, not sequential. Think you need to build
manufacturing of a vaccine before you know what’s working. If it doesn’t, let
me worry about it and we will write it off and throw it out.”
He was clearly impressed with the way his team responded to the challenge, saying:
“How fast we moved is not something you could expect from big, powerful
Pharma. This is speed that you would envy in an entrepreneurial founder-based biotech.”
Sharing is caring
From the beginning, Bourla openly authorised having discussions and sharing proprietary information with rival firms. A brave move in the often closeted, secretive world of big pharma. Bourla made Pfizer’s manufacturing capabilities available to small biotech concerns and is in talks to make large quantities of other companies’ Covid-19 drug candidates.
One Pfizer brand getting plenty of attention is Xeljanz, their blockbuster
anti-JAK rheumatoid arthritis pill that could damp down the massive immune response that overwhelms some Covid-19 patients. Pfizer is supporting a Xeljanz trial in Italian Covid-19 patients, as well as a U.S. trial that will test a different arthritis medicine, an experimental drug that targets the Irak-4 protein, against the virus.
It is not just Pfizer though: we’ve simply highlighted them because of the
low levels of trust the wider community has had in their brand, and because they’re now a great example of what the industry is doing to rebuild brand trust. There are many other mega pharmaceutical companies in the kill-Covid game: Johnson & Johnson, Sanofi, AstraZeneca, GSK and Roche included.
Here’s a mini roundup:
- Speed of development and partnership are characteristic of many players, ahead of the race is Moderna (working with the National Institute of Allergy and Infectious Diseases) with a trial under the aptly titled ‘Operation Warp Speed’ now in Phase 3.
- AstraZeneca has joined forces with GSK and Sanofi to play a socially responsible role in the search for a vaccine and its rapid production. More quietly, AZ has donated nine million face masks to struggling nations.
- GSK is scouring its portfolio of brands for ones that might impact COVID-19 patient treatment. They’re also investing heavily in trials of the best candidates.
- Eli Lilly is supporting diabetes patients who are encouraged to call the Lilly Diabetes Solution Center, where they can talk through their options with advisers (including switching to generics).
- In our own small way, at THE PLANNING SHOP, we are supporting the Hemophilia TalkShop online community as they support one-another in these unprecedented times. The RAM (Rare Advocacy Movement) Living with Rare Disease online community is another
heart-warming example where patients are turning out to be a great comfort and source of solace to each other.
There is one final example that convincingly tells us that trust has become
immensely important to pharma companies: Chinese clinicians are using an AbbVie HIV treatment to address coronavirus-related pneumonia. Kaletra (also known as Aluvia) contains anti-viral components that block virus replication. Although not yet approved as a treatment for coronavirus, Kaletra has shown efficacy across multiple trial cases.
AbbVie has donated $1.5 million worth of Kaletra to China for use as an
experimental treatment option.
Kaletra is vital to AbbVie’s commercial success, yet the Company has given
up some of the brand’s commercial potential by announcing in April that it
wouldn’t defend patent rights to Kaletra. In the event that Kaletra does prove effective against COVID-19, the move would allow competitors to create additional supply to satisfy demand that AbbVie alone can’t meet. That is an astonishing move of generosity that can only inspire admiration and trust.